ALLOX

AI- and genetics-enabled platform for discovering drugs targeting allosteric sites for oncology and other diseases.

Cover Block

Public sources

Field	Detail
Name	ALLOX
Tagline	AI- and genetics-enabled platform for discovering drugs targeting allosteric sites for oncology and other diseases [El Periódico, October 2026]
Headquarters	Barcelona, Spain [ALLOX, November 2023]
Founded	2023 [ALLOX, November 2023]
Stage	Seed [ALLOX, October 2026]
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout [ALLOX, November 2023]
Funding Label	$10M+
Total Disclosed	~$10,500,000 [ALLOX, October 2026]

Executive Summary

PUBLIC ALLOX is a Barcelona-based techbio spinout building an AI- and genetics-enabled platform to discover drugs against allosteric protein sites, and it merits investor attention now because it has paired a scientifically distinctive thesis with a newly disclosed $10.5 million seed round to fund platform expansion and pipeline buildout [ALLOX, November 2023] [GlobeNewswire, October 2026]. The company was founded in 2023 out of work developed in Ben Lehner's laboratory at the Centre for Genomic Regulation, with early backing from Asabys through Sabadell Asabys II in an undisclosed pre-seed round announced at launch [ALLOX, November 2023] [Asabys, November 2023].

The product claim is straightforward even if the biology is technically demanding: ALLOX says it combines experimental genetics, artificial intelligence, and energy-based models to identify regulatory "switches" on proteins and turn those findings into therapeutic programs, starting in oncology and potentially extending into immune-system and inflammatory diseases [ALLOX, November 2023] [El Periódico, October 2026] [biotech-spain.com]. The differentiation, according to public materials, rests less on a single model layer than on the integration of wet-lab genetics, computational biology, and allostery-focused drug design around targets that may be difficult to address through conventional active-site approaches [ALLOX, November 2023] [ALLOX, May 2025].

The founding team is unusually research-heavy, which fits the problem selection. CEO Júlia Domingo is described as a biologist and bioinformatician from the Lehner lab, while co-founders Pablo Baeza and André Faure also came through that research environment; Lehner, an ICREA professor at CRG and Head of Generative and Synthetic Genomics at the Wellcome Sanger Institute, serves as co-founder and scientific anchor [Ellipse, July 2024] [ALLOX, May 2025] [Ben Lehner | VIB Conferences].

On financing, public records support at least $10.5 million of disclosed funding, consisting of an undisclosed 2023 pre-seed and a $10.5 million seed announced in October 2026, led by Asabys through Sabadell Asabys II with participation from CDTI through SICC Innvierte and Institut Català de Finances [ALLOX, November 2023] [GlobeNewswire, October 2026] [Expansion, October 2026]. The business model appears to be a B2B techbio platform with the option to build an internal therapeutic pipeline, but the public record does not yet show named pharma customers, partnered programs, or clinical assets, which is the main execution gap to watch [ALLOX, May 2025] [GlobeNewswire, October 2026].

Over the next 12 to 18 months, the key markers are whether ALLOX can translate platform claims into disclosed preclinical programs, external validation from partners, or data that supports movement toward the clinic using the new seed capital [GlobeNewswire, October 2026] [Ara, October 2026]. The setup is promising, but at this stage the investability still turns on evidence that the scientific platform can generate repeatable drug-discovery outputs beyond the founding narrative and financing momentum [ALLOX, November 2023] [El Periódico, October 2026].

Lightly corroborated -- Core company, funding, and founder-role facts are corroborated by company materials and independent coverage, but product capability and forward pipeline claims remain materially company-led.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	$10M+ total disclosed, approximately $10.5M [GlobeNewswire, October 2026]

How the Company Got Here

Public sources The plain fact pattern is early but coherent. ALLOX is a Barcelona-based techbio company founded in 2023 and presented as a spin-out from the Centre for Genomic Regulation, built on work originating in Ben Lehner's laboratory [ALLOX, November 2023]. Public company materials describe a research platform aimed at discovering drugs that act on allosteric sites, with the business set up around internal therapeutic program creation rather than a marketed product at this stage [ALLOX, November 2023].

The founding team reflects that academic origin. ALLOX names Júlia Domingo, Ben Lehner, Pablo Baeza, and André Faure as co-founders, and public profiles identify Domingo as CEO, Baeza as Chief Discovery Officer, and Faure as Chief Development Officer [ALLOX, May 2025]. The same company materials place the business in Barcelona and tie its early scientific strategy to CRG research, which is the central organizing fact in the company's formation story [ALLOX, November 2023].

The milestone sequence is short and dateable. ALLOX publicly launched in November 2023 with backing from Sabadell Asabys II, the fund managed by Asabys Partners, in an undisclosed pre-seed round intended to support initial team building, facilities, and validation work [ALLOX, November 2023]. In October 2026, the company announced a $10.5 million seed financing led by Asabys through Sabadell Asabys II, with participation from CDTI through SICC Innvierte and the Institut Català de Finances, and also announced the appointment of Morten Graugaard as chair of the board [ALLOX, October 2026].

Lightly corroborated -- Primarily confirmed by ALLOX company materials, with company website support for founding, headquarters, team, and milestone chronology.

Product and Technology

MIXED The product story is still more scientific thesis than commercial surface, and that is the right place to start. ALLOX describes itself as an AI- and genetics-enabled drug discovery company focused on allosteric sites, meaning protein regions distinct from conventional active sites that can regulate protein behavior when bound by a molecule [ALLOX, November 2023]. In public materials, the company says its platform combines experimental genetics, artificial intelligence, and energy-based models to predict and design drugs against those allosteric sites [ALLOX, November 2023]; [biotech-spain.com].

The functional claim is that this approach can identify the "switches" controlling disease-relevant proteins and convert those findings into therapeutic programs, with oncology as the initial focus and immune-system and inflammatory diseases as possible adjacent applications [El Periódico, October 2026]; [ALLOX, May 2025]. That framing is consistent across company and press sources, but the public record does not yet show a named asset, a disclosed preclinical candidate, or a verified external validation package that would let investors judge hit generation, screening economics, or translation into development milestones [ALLOX, May 2025]; [El Periódico, October 2026].

A second point is that ALLOX appears to be building for internal pipeline creation rather than selling a finished software tool. Company materials describe the platform as a route to build proprietary therapeutic programs, and the spinout's origin in Ben Lehner's CRG lab suggests the core differentiation rests on biological insight and target-selection logic rather than on a standalone model layer [ALLOX, November 2023]; [ALLOX, May 2025]. A Seqera case study also places ALLOX in a computational biology workflow, which supports the view that the company is operating a research platform with meaningful compute infrastructure, though that source does not establish product performance or commercial partnerships [Seqera, June 2026].

Company-stated, unverified -- Core product and capability claims are primarily company-described, with partial repetition in press coverage and one third-party workflow reference from Seqera.

Where the Demand Sits

PUBLIC

The market matters now because ALLOX sits at the intersection of two areas attracting sustained pharmaceutical spend, precision oncology discovery and AI-enabled drug R&D, while targeting a harder-to-drug biological mechanism that conventional active-site programs often miss [ALLOX, November 2023] [El Periódico, October 2026].

Public sources in the record do not provide a cited TAM, SAM, or SOM for allosteric drug discovery specifically, and this is a meaningful omission because the commercial path could range from platform partnerships to wholly owned therapeutics programs [ALLOX, May 2025]. The safer framing is by analogy: ALLOX is pursuing drug discovery infrastructure for oncology first, with stated applicability to immune-system and inflammatory diseases later, which places it inside broader biotech R&D budgets rather than a neatly bounded software market [El Periódico, October 2026] [biotech-spain.com]. That matters for investors because budget ownership, timelines, and proof points will look more like therapeutic platform companies than enterprise AI vendors [ALLOX, May 2025].

Demand drivers are visible even without a clean market-size figure. ALLOX argues that allostery can surface regulatory sites distinct from conventional active sites, a route that in principle expands the set of proteins that can be modulated with drugs [ALLOX, November 2023]. The company also says it combines experimental genetics, artificial intelligence, and energy-based models, which maps to a wider industry push to improve target selection and reduce early-stage attrition in drug discovery, especially in oncology where biological complexity and failure rates remain high [ALLOX, November 2023] [ALLOX, May 2025].

The adjacent markets are clearer than the core market sizing. One adjacency is computational biology infrastructure, illustrated by Seqera's published case study naming ALLOX as a biotechnology startup using computational infrastructure in its research workflow, though that case study does not establish a commercial partnership or spend level [Seqera, June 2026]. Another is the broader market for platform biotech collaborations with pharmaceutical companies, since ALLOX's likely buyers are pharma and biotech groups seeking new targets, candidates, or discovery programs, even as the company also describes an internal pipeline ambition [ALLOX, May 2025].

Market lens	Public evidence	Implication for ALLOX
Core category	Allosteric drug discovery platform using genetics, AI, and energy-based models [ALLOX, November 2023]	Category is scientifically differentiated, but not supported here by third-party market sizing
Initial beachhead	Oncology [El Periódico, October 2026]	Large unmet-need area, but long validation cycles and expensive biology
Expansion adjacency	Immune-system and inflammatory diseases [El Periódico, October 2026]	Broadens eventual program scope if the platform generalizes across targets
Workflow adjacency	Computational research infrastructure in biotech [Seqera, June 2026]	Suggests dependence on scalable compute and data workflows, not just wet lab capability

The table shows the central feature of this market: breadth of possible application is visible in public materials, but monetization boundaries are still early. For now, the better read is that ALLOX addresses a wide pharmaceutical R&D problem set, while its own addressable revenue will depend on whether it proves repeatable target discovery, partner interest, or internal asset progression first [ALLOX, May 2025].

Regulatory and macro forces cut both ways. Support from CDTI through SICC Innvierte and from the Institut Català de Finances in the 2026 seed round points to a European funding environment that remains open to strategic biotech and deeptech formation [ALLOX, October 2026]. At the same time, if ALLOX advances from platform work toward clinical-stage development, the company would move into the slower, more capital-intensive regulatory regime governing therapeutic development, where scientific promise does not shorten preclinical and clinical timelines [ALLOX, October 2026].

Lightly corroborated -- This section relies primarily on company materials and one independent media report, with no third-party market-sizing dataset in the provided record.

Competitive Landscape

MIXED ALLOX is positioned less against classical biotech drug developers than against a mix of allostery-focused discovery efforts, broader oncology platforms, and better-capitalized therapeutic companies that already control clinical assets.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
ALLOX	Barcelona-based techbio spin-out using experimental genetics, AI, and energy-based models to discover drugs targeting allosteric protein sites, initially in oncology	Seed; at least $10.5M disclosed financing	Built around allosteric-site discovery and internal therapeutic pipeline creation from CRG-originated science	[ALLOX, November 2023]; [GlobeNewswire, October 2026]
ALX Oncology	Oncology company	Public company	Existing public-market access and clinical-stage oncology focus create a different financing and development profile from an early discovery platform	[Crunchbase, retrieved 2026]
Allogene Therapeutics	Oncology cell therapy company	Public company	Clinical development footprint and manufacturing complexity place it in a more mature but capital-intensive category	[Crunchbase, retrieved 2026]
Allos Therapeutics	Oncology therapeutics company	Acquired	Historical comparator showing that oncology asset companies can exit through acquisition rather than remain platform-led	[Crunchbase, retrieved 2026]

The table reads unevenly because the named public comparators are not close product matches, and that in itself is useful. ALLOX appears to sit in a narrower niche, allosteric drug discovery enabled by computational and experimental biology, while ALX Oncology and Allogene Therapeutics are asset-heavy oncology developers with public-company scale and clinical execution demands [ALLOX, November 2023]; [Crunchbase, retrieved 2026]. Allos Therapeutics is best treated as a historical oncology benchmark rather than a live platform rival [Crunchbase, retrieved 2026].

The competitive map therefore has to be drawn by segment, not by name alone. Incumbents are large pharmaceutical discovery organizations and established biotechs that already run internal oncology target-discovery programs, even if they are not named in the source set; adjacent substitutes are companies pursuing the same disease areas through modalities that do not depend on allosteric-site biology, including cell therapy and conventional small-molecule programs, as illustrated by Allogene Therapeutics and ALX Oncology [Crunchbase, retrieved 2026]. Challengers closest to ALLOX's lane are other techbio and structure-based discovery groups, but the public source base here supports ALLOX's own positioning more clearly than it identifies a clean set of direct allostery peers [ALLOX, May 2025].

Where ALLOX appears strongest today is scientific origin and team fit. The company was spun out from the Centre for Genomic Regulation and built on work from Ben Lehner's laboratory, with founders spanning experimental genetics, computational biochemistry, and bioinformatics, which gives some credibility to the claim that the differentiation rests on the dataset and biological insight rather than the model layer alone [ALLOX, November 2023]; [Ellipse, July 2024]; [ALLOX, May 2025]. That edge is real but perishable. It tends to hold only while the company can convert lab-specific know-how into proprietary data and program output faster than better-funded discovery organizations can reproduce the workflow.

The main exposure is scale, not concept. ALX Oncology and Allogene Therapeutics each operate from a more advanced financing and development base, which matters because oncology rewards companies that can move from discovery claims to clinical evidence, and ALLOX has not publicly disclosed named pharmaceutical customers, clinical programs, or partnered milestones in the material reviewed here [Crunchbase, retrieved 2026]; [GlobeNewswire, October 2026]. That leaves the company vulnerable if larger competitors or adjacent oncology developers show stronger translational progress before ALLOX can demonstrate that allosteric-site discovery produces assets that are not only novel, but developable.

The most plausible 18-month scenario is bifurcated. Winner if X: ALLOX, if the seed financing is translated into early preclinical programs or external validation that shows its allostery platform can repeatedly generate actionable targets or candidates [GlobeNewswire, October 2026]. Loser if Y: ALLOX, if better-capitalized oncology developers such as ALX Oncology or adjacent therapeutic platforms continue to compound clinical or partnering evidence while ALLOX remains at the platform-narrative stage, because the market usually rewards proof of development more than elegance of discovery architecture [Crunchbase, retrieved 2026]; [ALLOX, May 2025].

Opportunity

Upside case

PUBLIC The prize here is unusually large for a company this early: if ALLOX can repeatedly turn allosteric biology into drug programs that larger biopharma teams cannot find on their own, it could grow from a Barcelona spinout into a platform company that matters both as a discovery engine and as an asset creator in oncology and adjacent disease areas [ALLOX, November 2023] [El Periódico, October 2026].

The headline opportunity is not simply to sell software into drug discovery. On the public record, ALLOX is building a platform that combines experimental genetics, artificial intelligence, and energy-based models to identify allosteric sites and convert them into therapeutic programs, with an initial focus on oncology and stated potential in immune-system and inflammatory disease [ALLOX, November 2023] [biotech-spain.com] [El Periódico, October 2026]. If that platform works in a repeatable way, the business could plausibly become a multi-asset techbio company whose value is driven by proprietary programs, selective partnerships, and a growing internal map of disease-relevant protein control points, rather than by one-off research services alone [ALLOX, May 2025] [ALLOX, October 2026]. What makes that outcome reachable, rather than purely aspirational, is the combination of a CRG-origin scientific base, a founding team drawn from Ben Lehner's research environment, and enough disclosed capital to keep building the platform past formation stage [ALLOX, November 2023] [Ellipse, July 2024] [GlobeNewswire, October 2026].

The public evidence supports a few distinct paths to scale, each with a different trigger and capital profile.

Scenario	What happens	Catalyst	Why it's plausible
Platform-to-pipeline winner	ALLOX uses its discovery stack to nominate multiple internal programs and matures into a therapeutics company with meaningful asset value	Early preclinical data from oncology programs and continued financing to move toward clinical-stage development	The company says seed proceeds will support its platform, proprietary AI models, and internal pipeline, with the stated aim of progressing toward clinical-stage development [GlobeNewswire, October 2026]. Its platform is built specifically to identify allosteric control sites and translate them into therapies [ALLOX, November 2023] [El Periódico, October 2026].
Partnered discovery engine	ALLOX becomes a preferred external discovery partner for biopharma groups seeking novel targets or mechanisms around hard-to-drug proteins	A first disclosed pharma or biotech partnership that validates external demand for its approach	Public materials frame the company around discovering drugs and building therapeutic programs for disease-relevant proteins, and the likely commercial counterparties are pharma and biotech companies rather than end users [ALLOX, May 2025] [ALLOX, November 2023].
Allostery specialist with option value	ALLOX establishes category authority in allosteric drug discovery, then compounds value through a mix of partnered and wholly owned programs across oncology and inflammatory biology	Strong scientific validation around one or more disease-relevant "switches" and board-level scaling support	The company is explicitly organized around allostery as the core wedge, began with oncology, and has already added a board chair with life-sciences venture, business development, and M&A experience [ALLOX, November 2023] [El Periódico, October 2026] [Parc Científic de Barcelona, October 2026].

The compounding mechanism, if it emerges, is straightforward in concept even if difficult in practice. Each successful identification of an allosteric site should improve ALLOX's ability to prioritize the next one, because the company says its platform integrates experimental genetics with AI and energy-based models, and because internally generated validation data can feed future discovery cycles [ALLOX, November 2023] [GlobeNewswire, October 2026]. In biotech terms, that is the closest thing this model has to a flywheel: more biological observations can sharpen model performance, stronger model performance can accelerate program selection, and a larger proprietary program base can create more opportunities for partnerships or asset financing. The flywheel is only lightly evidenced in public today, but two signals matter: the company has raised follow-on capital from its original backer Asabys and is dedicating seed proceeds to expand both the experimental platform and proprietary AI models, which suggests investors see platform accumulation, not a single-shot asset bet, as the core value driver [Asabys, November 2023] [GlobeNewswire, October 2026].

The size of the win is best framed through scenario logic, not certainty. A useful public comparable is Allogene Therapeutics, a public oncology biotech whose enterprise scale shows how valuable platform-backed drug pipelines can become when public markets credit both science and pipeline depth, although Allogene works in cell therapy rather than allosteric small-molecule discovery [Allogene Therapeutics, October 2026]. Under a successful platform-to-pipeline scenario, ALLOX could be worth venture-scale billions at maturity (scenario, not a forecast) if it demonstrates that its discovery engine repeatedly yields differentiated assets and converts that into either clinical proof points or high-value partnerships. A more conservative but still substantial outcome would resemble a strategic acquisition of the platform and early pipeline by a larger drug developer seeking a durable edge in target discovery and mechanism design, particularly if ALLOX can show that allosteric approaches open proteins that conventional active-site strategies miss [ALLOX, November 2023] [ALLOX, October 2026].

Lightly corroborated -- Core company, funding, and team claims are supported by company materials and multiple news reports, but the upside case relies materially on company-described platform capabilities and scenario analysis rather than independently verified operating outcomes.

Sources